433 related articles for article (PubMed ID: 16093982)
1. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
[TBL] [Abstract][Full Text] [Related]
2. The fate of the medically castrated testis: expectation versus reality.
Issa MM; Krishnan A; Bouet R; Young MR; Hood N; Petros JA
J Urol; 2004 Sep; 172(3):1042-4. PubMed ID: 15311033
[TBL] [Abstract][Full Text] [Related]
3. Spermatic cord anesthesia block for scrotal procedures in outpatient clinic setting.
Issa MM; Hsiao K; Bassel YS; Bouet R; Young MR; Petros JA
J Urol; 2004 Dec; 172(6 Pt 1):2358-61. PubMed ID: 15538267
[TBL] [Abstract][Full Text] [Related]
4. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
5. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
6. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
7. Re: Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Barbalias GA
J Urol; 2006 May; 175(5):1966-7; author reply 1967. PubMed ID: 16600812
[No Abstract] [Full Text] [Related]
8. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
10. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
11. Outpatient arthroscopic knee surgery under combined local and intravenous propofol anesthesia in children and adolescents.
Maldini B; Miskulin M
Paediatr Anaesth; 2006 Nov; 16(11):1125-32. PubMed ID: 17040300
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for prostate cancer: effects on hand function.
Soyupek F; Soyupek S; Perk H; Ozorak A
Urol Oncol; 2008; 26(2):141-6. PubMed ID: 18312932
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer.
Penson DF; Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M
J Urol; 2005 Aug; 174(2):547-52; discussion 552. PubMed ID: 16006889
[TBL] [Abstract][Full Text] [Related]
14. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
[TBL] [Abstract][Full Text] [Related]
15. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
Kawamura K
Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
[TBL] [Abstract][Full Text] [Related]
16. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
17. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
18. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
19. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
20. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
Oefelein MG
J Urol; 1998 Nov; 160(5):1685-8. PubMed ID: 9783932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
